Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This was a retrospective non-interventional study (NIS) of adult (≥18 years) multiple sclerosis (MS) patients on ofatumumab therapy in the United Kingdom (UK) using secondary data. UK MS centers with National Health Service (NHS) databases and/or homecare and pharmacy services prescribing ofatumumab were identified and recruited for study participation using a feasibility assessment exercise. The study index identification window spanned from 26 March 2021 to 30 June 2023 (or latest data available prior to start of study data extraction). The index date was defined as the first date ofatumumab was dispensed or injected within the index identification window. From index date, patients were followed up until death, up to 13 months after index date, loss to follow-up, or end of study index identification window (whichever came first).
For patients who consented to the use of their data, participating sites transcribed protocol required patient data from existing individual patient medical records into an electronic case report form (eCRF). The end of study was defined as the date of last data query resolution (i.e., all data had been recorded in the eCRF and all data queries resolved to allow database lock to occur). This ensured that all data was available to answer the research questions in the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Overall MS Cohort | Adult patients with relapsing-remitting multiple sclerosis (RMS) who were prescribed ofatumumab from either an MS clinic participating in the Kesimpta Connect (KC) patient support program (PSP) or an MS clinic not participating in the KC PSP. | ||
| KC PSP User Cohort | Adult patients with RMS who were prescribed ofatumumab from an MS clinic participating in the KC PSP. | ||
| Non-KC PSP User Cohort | Adult patients with RMS who were prescribed ofatumumab from an MS clinic not participating in the KC PSP. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Medical Possession Ratio (MPR) | MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. | Up to 13 months |
| Number of Patients by MPR Category | MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. MPR categories:
| Up to 13 months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Patients by Demographic Category | Demographic categories included:
| Baseline |
| Time From MS Diagnosis to Ofatumumab Initiation |
Not provided
Inclusion criteria:
Patients were included in the study if they met all of the following criteria:
Patient was prescribed ofatumumab within the UK approved marketing authorization
Patient initiated ofatumumab via participating MS clinic with or without KC PSP
Patients initiated ofatumumab during the index identification window
Authorized to collect study data:
Specifically for adherence analyses: Patients were required to have a minimum of 6 months of follow-up post index date available to make this assessment
Specifically for clinical effectiveness analyses: Patients were required to have a minimum of 6 months look-back pre-index date and minimum 6 months follow-up post index date available to make this assessment.
Exclusion criteria:
Patients were excluded from the study if they met the following criteria:
• Patient prescribed ofatumumab outside the approved marketing authorization (i.e., under off-label prescribing) at any point within the patients record
Not provided
Not provided
Not provided
This was a retrospective, non-interventional cohort study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis | East Hanover | New Jersey | 07936 | United States |
Not provided
| ID | Term |
|---|---|
| D020529 | Multiple Sclerosis, Relapsing-Remitting |
| D055118 | Medication Adherence |
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline |
| Number of Patients by Comorbidity | Baseline |
| Number of Patients who Received at Least one DMT Prior to Ofatumumab Initiation | Up to 13 months |
| Number of Prior DMTs Reported | Up to 13 months |
| Number of Patients by Prior DMT Category | DMT categories included:
| Up to 13 months |
| Number of Patients by Reason for Switch from Other DMT to Ofatumumab | Up to 13 months |
| Individual Annualized Relapse Rate (ARR) Before Ofatumumab Initiation | Individual ARR was derived per patient as [(number of confirmed MS relapses) / (time at risk (years)]. | Up to 13 months |
| Total ARR Before Ofatumumab Initiation | Total ARR was derived as [(total number of confirmed MS relapses) / (total number of person-years at risk)]. | Up to 13 months |
| Individual ARR After Ofatumumab Initiation | Individual ARR was derived per patient as [(number of confirmed MS relapses) / (time at risk (years)]. | Up to 13 months |
| Total ARR After Ofatumumab Initiation | Total ARR was derived as [(total number of confirmed MS relapses) / (total number of person-years at risk)]. | Up to 13 months |
| Average Expanded Disability Status Scale (EDSS) Score Before Ofatumumab Initiation | The EDSS is a tool used to measure how much a person is affected by their MS. It consists of 8 functional systems (FS): Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the patients score is determined between 0 (normal) and 10 (death due to MS). | Up to 13 months |
| Average EDSS Score After Ofatumumab Initiation | The EDSS is a tool used to measure how much a person is affected by their MS. It consists of 8 functional systems (FS): Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the patients score is determined between 0 (normal) and 10 (death due to MS). | Up to 13 months |
| Absolute Change in Average EDSS Score | Absolute change in average EDSS score between 2 study periods was derived as: [mean EDSS score during the follow-up period] - [mean EDSS score during the pre-index period]. The index date was defined as the first date ofatumumab was dispensed or injected within the index identification window. The EDSS is a tool used to measure how much a person is affected by their MS. It consists of 8 functional systems (FS): Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the patients score is determined between 0 (normal) and 10 (death due to MS). | Up to 26 months |
| Average Number of T1 and T2 Lesions Before Ofatumumab Initiation | Up to 13 months |
| Average Number of T1 and T2 Lesions After Ofatumumab Initiation | Up to 13 months |
| Individual ARR After Ofatumumab Initiation by MPR Category | Individual ARR was derived per patient as [(number of confirmed MS relapses) / (time at risk (years)]. MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. MPR categories:
| Up to 13 months |
| Total ARR After Ofatumumab Initiation by MPR Category | Total ARR was derived as [(total number of confirmed MS relapses) / (total number of person-years at risk)]. MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. MPR categories:
| Up to 13 months |
| Average EDSS Score Before Ofatumumab Initiation by MPR Category | The EDSS is a tool used to measure how much a person is affected by their MS. It consists of 8 functional systems (FS): Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the patients score is determined between 0 (normal) and 10 (death due to MS). MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. MPR categories:
| Up to 13 months |
| Average EDSS Score After Ofatumumab Initiation by MPR Category | The EDSS is a tool used to measure how much a person is affected by their MS. It consists of 8 functional systems (FS): Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the patients score is determined between 0 (normal) and 10 (death due to MS). MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. MPR categories:
| Up to 13 months |
| Absolute Change in Average EDSS Score by MPR Category | Absolute change in average EDSS score between 2 study periods was derived as: [mean EDSS score during the follow-up period] - [mean EDSS score during the pre-index period]. The index date was defined as the first date ofatumumab was dispensed or injected within the index identification window. The EDSS is a tool used to measure how much a person is affected by their MS. It consists of 8 functional systems (FS): Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the patients score was determined between 0 (normal) and 10 (death due to MS). MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. MPR categories:
| Up to 26 months |
| Number of Patients per MPR Category by Type of KC PSP Services Received | KC PSP services included face-to-face nurse visits, virtual nurse visits, and mobile text reminders. MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. MPR categories:
| Up to 13 months |
| Number of Medical Visits After Ofatumumab Initiation | Medical visits included accident and emergency (A&E) visits, inpatient visits, and outpatient visits. | Up to 13 months |
| Annualized Medical Visit Rate After Ofatumumab Initiation | Annualized medical visit rate per patient was calculated as [(number of events during follow-up period) / (time at risk (years) during follow-up period)]. Rates were calculated for the following types of medical visits: A&E visits, inpatient visits, and outpatient visits. | Up to 13 months |
| Number of MS-related Medical Visits After Ofatumumab Initiation | MS-related medical visits included A&E visits, inpatient visits, and outpatient visits. | Up to 13 months |
| Annualized MS-related Medical Visit Rate After Ofatumumab Initiation | Annualized MS-related medical visit rate per patient was calculated as [(number of events during follow-up period) / (time at risk (years) during follow-up period)]. Rates were calculated for the following types of MS-related medical visits: A&E visits, inpatient visits, and outpatient visits. | Up to 13 months |
| Number of Patients With Medically Reported Adherence (MRA) After Ofatumumab Initiation | Full adherence was defined as no record of dose/s missed between ofatumumab initiation and the point at which the patient was censored. Partial adherence was defined as a record of at least one dose missed between ofatumumab initiation and the point at which the patient was censored. The date of censoring was defined as the earliest of the following:
| Up to 13 months |
| Number of Patients by Reason for Discontinuation of Ofatumumab | Up to 13 months |
| Number of Patients who Switched From Ofatumumab to an Alternative DMT | Up to 13 months |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D010349 | Patient Compliance |
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
| D001519 | Behavior |